Leptin and the cardiovascular system: A review

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 2, 2007, Pages 100-109

  Ashwin, Patel J ^a   Dilipbhai, Patel J ^b  

^a NIRMA UNIVERSITY   (India)

^b Arihant School of Pharmacy   (India)

Author keywords

Angiogenesis; Cardiovascular diseases; Hypertension; Leptin; Leptin receptors; Leptin resistance; Neuropeptides; Obesity

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; AMINO ACID DERIVATIVE; AZETIDINONE DERIVATIVE; C REACTIVE PROTEIN; CAPTOPRIL; CHOLECYSTOKININ; CILIARY NEUROTROPHIC FACTOR; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOTROPIN RELEASING FACTOR; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; FIBRINOLYTIC AGENT; GROWTH HORMONE RELEASING FACTOR; JANUS KINASE; LEPTIN; LEPTIN RECEPTOR; LOSARTAN; MELANIN CONCENTRATING HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; MONOAMINE OXIDASE B INHIBITOR; NEUROPEPTIDE Y; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHORAMIDON; PIOGLITAZONE; PLACEBO; PROOPIOMELANOCORTIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STAT3 PROTEIN; UNINDEXED DRUG;

ANGIOGENESIS; ARCUATE NUCLEUS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY STENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EATING DISORDER; GENE MUTATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; HYPERTENSION; HYPOTHALAMUS; IN-STENT RESTENOSIS; INCIDENCE; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; CARDIOVASCULAR SYSTEM; HUMANS; LEPTIN; MODELS, BIOLOGICAL; OBESITY;

EID: 34250712844     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007780832533     Document Type: Review

References (112)

1. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 137-413.
2. Zhang Y, Proenca R, Maffai M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
3. Butler, A. A., Trevaskis, J.: WO07019426 (2007).
4. Zhang F, Babinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature 1997; 387: 206-209.
5. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989; 58: 573-581.
6. Larsen A, Davis T, Curtis BM, et al. Expression cloning of a human granulocyte colony-stimulating factor receptor: a structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains. J Exp Med 1990; 172: 1559-1570.
7. Gearing DP, Thut CJ, VandenBos T, et al. Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. EMBO J 1991; 10: 2839-2848.
8. Lee GH, Proenca R, Montez JM, Carroll K, Darvishzadeh JG, Lee JI. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379: 632-635.
9. Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res 2004; 59: 305-331.
10. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996; 17: 305-311.
11. Tartaglia LA. The Leptin Receptor. J Biol Chem 1997; 272: 6093-6096.
12. Hegyi K, Fulop K, Kovacs K, Toth S, Falus A. Leptin induced signal transduction pathways. Cell Biol Int 2004; 28: 159-169.
13. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999; 22: 221-232.
14. Bates SH, Steams WH, Schubert M. STAT3 signaling is required for leptin regulation of energy balance but not reproduction. Nature 2003; 421: 856-59.
15. Kas MJ, Bruijnzeel AW, Haanstra JR, Wiegant VM, Adan RA. Differential regulation of agouti-related protein and neuropeptide Y in hypothalamic neurons following a stressful event. J Mol Endocrinol 2005; 35: 159-164.
16. Cowley MA, Smart JL, Rubinstein M. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001; 411: 480-484.
17. Seeley RJ, Yagaloff KA, Fisher SL. Melanocortin receptors in leptin effects. Nature 1997; 390: 349.
18. Cumin F, Baum HP, Levens N. Leptin is cleared from the circulation primarily by the kidney. Int J Obes Relat Metab Disord 1996; 20: 1120-1126.
19. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159-161.
20. Muoio DM, Dohm GL, Fiedorek FT Jr, Tapscott EB, Coleman RA. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes 1997; 46: 1360-1363.
21. Banks WA, Coon AB, Robinson SM, et al. Triglycerides induce leptin resistance at the blood brain barrier. Diabetes 2004; 53: 1253-1260.
22. El-Haschimi K, Pierroz DD, Hileman SM, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000; 12: 1827-1832.
23. Rossetti, L., Lam, T., Gutierrez-Juarez, R., Herlands, L.: WO07002365 (2007).
24. Chen K, Kelley DE, Biseello A, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006; 12: 425-432.
25. Zhou Y-T, Shimabukuro M, Wang M-Y, et al. Role of PPARa in disease of Pancreatic β cell. Proc Natl Acad Sci USA 1998; 95: 8898-8903.
26. Das UN. Essential fatty acids, lipid peroxidation and apoptosis. Prostaglandins Leukot Essent Fatty Acid 1999; 61: 157-167.
27. Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells. Novel role of leptin. Proc Natl Acad Sci USA 1999; 96: 2327-2332.
28. Pinneda-Torra I, Gervois P, Staels B. Peroxisome proliferator activated receptor α in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 1999; 10: 151-159.
29. Mark AL, Correia ML, Rahmouni K, Haynes WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 2002; 20: 1245-1250.
30. Haynes WG. Role of leptin in obesity related hypertension. Exp Physiol 2005; 90: 683-688.
31. Dey, D., Nag, A., Pandey, B., Balse, P., Neogi, P., Nag, B.: WO07005774 (2007).
32. Lee DW, Leinung MC, Rozhavskaya-Arena M, Grasso P. Leptin and the treatment of obesity: its current status. Eur J Pharmacol 2002; 440: 129-139.
33. Licinio J, Caglayan S, Ozata M. Phenotypic effect of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism and behavior an leptin deficient adults. Proc Natl Acad Sci USA 2004; 101: 4531-4536.
34. Carro E, Senaris R, Considine RV, Casanuevo FF, Dieguez C. Regulation of in vivo growth hormone secretion by leptin. Endocrinol 1997; 138: 2203-2206.
35. Fantuzzi G, Faggioni R: Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000; 68: 437-446.
36. Blaine H, Vuillemin A, Guillemin F, et al. Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinal Metab 2002; 87: 1030-1035.
37. Elefteriou F, Deok J, Takeda S, Starbuck M. leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005; 434: 514.
38. Park HY, Kwon HM, Lim HJ, et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 2001; 33: 95-102.
39. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-1540.
40. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Inoune H. Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res 2003; 65: 186-190.
41. Guilmeau S, Buyse M, Bado A. Gastric leptin: a new manager of gastrointestinal function. Curr Opin Pharmacol 2004; 4: 561-566.
42. Popovic V, Duntas LH. Brain somatic cross-talk: ghrelin, leptin and ultimate challengers of obesity. Nutr Neurosci 2005; 8: 1-5.
43. Chan JL, Mantzoros CS. Role of leptin in energy deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhea and anorexia nervosa. Lancet 2005; 366: 74-84.
44. Grinspoon S, Gulick T, Askari H, et al. Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab 1996; 81: 3961-3863
45. Mantzoros CS. Leptin and the hypothalamus: neuroendocrine control of food intake. Mol Psychiatry 1999; 4: 8-12.
46. Benoit SC, Clegg DJ, Seeley RJ, Woods SC. Insulin and leptin as adiposity signals. Recent Prog Horm Res 2004; 59: 267-285.
47. Wolk R, Somers VK. Leptin and vascular Function: Friend or Foe? Eur Heart J 2006; 27: 2263-2265.
48. Rahmouni K, Haynes WG. Leptin and the cardiovascular system. Recent Prog Horm Res 2004; 59: 225-244.
49. Söderberg S, Ahrén B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246: 409-418.
50. Wallace M, McMahon AD, Packard CJ, et al. Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study. Circulation 2001; 104: 3052-3056.
51. Couillard C, Lamarche B, Mauriege P, et al. Plasma leptin concentrations: gender differences and associations with metabolic risk factors for cardiovascular disease. Diabetologia 1997; 40: 1178-1184.
52. Piemonti L, Calori G, Mercalli A, et al. Fasting plasma leptin, tumor necrosis factor- {alpha} receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: Impact on cardiovascular mortality. Diabetes Care 2003; 26: 2883-2889.
53. Iribarren C, Husson G, Go AS, et al. Plasma leptin levels and coronary artery calcification in older adults. J Clin Endocrinol Metab 2007; 92: 729-732.
54. Reilly MP, Iqbal N, Schutta M, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004, 89: 3872-3878.
55. Hare, J.M., Barouch, L.A., Berkowitz, D.E.: WO07019302 (2007).
56. Barouch LA, Berkowitz DE, Harrison RW, Donnell CP, Hare JM, Disruption of Leptin Signaling Contributes to Cardiac Hypertrophy Independently of Body Weight in Mice. Circulation 2003; 108: 754-759.
57. Dong F, Zhang, X, Yang X, et al. Impaired cardiac contractile function in ventricular myocytes from Leptin-deficient ob/ob obese mice. J Endocrin 2006; 188: 25-36.
58. Dong F, Zhang X, Ren J. Receptor-NADPH Oxidase Pathway Leptin Regulates Cardiomyocyte Contractile Function through Endothelin-1. Hypertension 2006; 47: 222-229.
59. Rajapurohitam V, Javadov S, Purdham DM, Kirshenbaum LA, Karmazyn M. An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1. J Mol Cell Cardiol 2006; 41: 265-274.
60. Zeidan A, Pardham DM, Rajapurohitam V, Javadov S, Chakrabarti S, Karmazyn M. Leptin Induces Vascular Smooth Muscle Cell Hypertrophy through Angiotensin II- and Endothelin-1-Dependent Mechanisms and Mediates Stretch-Induced Hypertrophy. J Pharmacol Exp Ther 2005; 315; 1075-1084.
61. Sader S, Nian M, Liu P. Leptin: A Novel Link between Obesity, Diabetes, Cardiovascular Risk and Ventricular Hypertrophy. Circulation 2003; 108: 644-646.
62. Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation 2002; 106: 1904-1905.
63. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999; 13: 1231-1238.
64. Sundell J, Huupponen R, Raitakari OT, Nuutila P, Knuuti J. High serum leptin is associated with attenuated coronary vasoreactivity. Obesity Research 2003; 11: 776-782.
65. Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002; 51: 168-173.
66. Lembo G, Vecchione C, Fratta L, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49: 293-297.
67. Winters B, Mo Z, Brooks-Asplund E, et al. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice. J Appl Physiol 2000; 89: 2382-2390.
68. Kimura K, Tsuda K, Baba A, et al. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun 2000; 273: 745-749.
69. Schindler TH, Cardenas J, Prior JO, et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 2006; 47; 1188-1195.
70. Frühbeck G. Pivotal Role of Nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999; 48:903-908.
71. Mukherjee R, Villarreal D, Reams GP, Freeman RH, Tchoukina I, Spear RM. Leptin as a common link to obesity and hypertension. Drugs Today (Barc) 2005; 41: 687-95.
72. Bravo PE, Morse S, Borne DM, Aguilar EA, Reisin E. Leptin and hypertension in obesity. Vasc Health Risk Manag 2006; 2: 163-169.
73. Mcelroy, J.F., Chorvat, R.J., Rajagopalan, P.: WO07008963 (2007).
74. Mastronardi CA, Yu WH, McCann SM. Resting and circadian release of nitric oxide is controlled by leptin in male rats. Proc Natl Acad Sci USA 2002; 99: 5721-5726.
75. Lembo G, Vecchione C, Fratta L, Marino G, De Santis D, Trimarco-B. Leptin induces nitric oxide-mediated vaso-relaxation in aortic rings of WKY rats (Abstract). Hypertension 1998; 32: 599.
76. Wu X, Makynen H, Kahonen M, Arvola P, Porati I. Mesenteric arterial function in vitro in three models of experimental hypertension. J Hypertens 1996; 14: 365-372.
77. Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon III RO, Panza JA. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation 1998; 97: 851-856.
78. Jerzy B. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006; 24: 789-801.
79. Correia G, Lima M, Hayens, Geofrey W. Leptin, obesity and cardiovascular disease. Curr Opi Nephro Hyperten 2004; 13: 215-223.
80. Rodriguez A, Fruhbeck G, Gomez-Ambrosi J, et al. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. J Hypertens 2006; 24: 1589-1597.
81. Meisel SR, Ellis M, Pariente C, et al. Serum leptin levels increase following acute myocardial infarction. Cardiology 2004; 95: 206-211.
82. Amasyali B, Aytemir K, Kose S, et al. Admission plasma leptin level strongly correlates with the success of thrombolytic therapy in patients with acute myocardial infarction. Angiology 2007; 57: 671-680.
83. Depaoli, A.M., Taylor, S.I., Oral, E.A., Garg, A.: US20077183254B2 ( 2007).
84. Wallerstedt SM, Eriksson AL, Niklason A, Ohlsson C, Hedner T. Serum leptin and myocardial infarction in hypertension. Blood Pressure 2004; 13; 243-246.
85. Nishio K. Shigemitsu M, Kusuyama T, et al. Insulin resistance in nondiabetic patients with acute myocardial infarction. Cardiovasc Revasc Med 2006; 7: 54-60.
86. Nishio, K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes care 2006; 29: 101-106.
87. Marx N, Wöhrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005; 112: 2792-2798.
88. Schömig A, Kastrati A, Wessely R. Prevention of Restenosis by Systemic Drug Therapy: Back to the Future? Circulation 2005; 112; 2759-2761.
89. Taneli F, Yegane S, Ulman C, et al. Increased serum leptin concentrations in patients with chronic stable angina pectoris and ST-elevated myocardial infarction. Angiology 2006; 57: 267-272.
90. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002; 287: 1706-1709.
91. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Intern J Obesity 2001; 25: 805-810.
92. Pfefferkorn, J.A, Trivedi, B.K: WO07015161 (2007).
93. Tabibiazar R, Tsao P.S., Quertermous, T., Turnbull; B.K., Olshen, R.A., Hytopoulos, E.: WO07002677 (2007).
94. Knudson JD, Dincer UD, Zhang C, et al. Leptin are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol 2005, 289: 1148-1156.
95. Jin, X, Fakuda N, Su J, et al. Effects of leptin on endothelial function with OB-RB gene transfer in Zucker fatty rats. Atherosclerosis 2003, 169: 225-233.
96. Tanaka H, Safar ME. Influentue of lifestyle modification on arterial stiffness and wave reflections. Am J Hypertens 2005; 18:137-144.
97. Oda A, Taniguchi T, Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration, Kobe J Med Sci 2001; 47: 141-150.
98. Singhal A, Farooqi IS, Cole TJ, et al. Influence of Leptin on Arterial Distensibility: A Novel Link Between Obesity and Cardiovascular Disease? Circulation 2002; 106; 1919-1924.
99. Karaduman M, Oktenli C, Musabak U, et al. Leptin, soluble interleukin-6 receptor C-reactive protein and soluble vascular cell adhesion molecule-1 levels in human coronary atherosclerotic plaque. Clin Exp Immunol 2006; 143: 452-457.
100. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189:47-60.
101. Jaleel F, Jaleel A, Aftab J, Rahman MA. Leptin and blood lipid levels in postmenopausal diabetic women with and without complication of ischemic heart disease. Med Sci Monit 2006; 12: CR 382-386.
102. Bodary PF, Gu S, Shen Y, et al. Recombinant Leptin Promotes Atherosclerosis and Thrombosis in Apolipoprotein E-Deficient Mice. Arterioscler Thromb Vasc Biol 2005; 25; 119-122.
103. Wolk R, Berger P, Lennon R. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004, 44: 1819-1824.
104. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48:426-429.
105. Ekmekci H, Ekmekci OB, Sonmez H, et al. Evaluation of fibronectin, vitronectin, and leptin levels in coronary artery disease: impacts on thrombosis and thrombolysis. Clin Appl Thromb Hemost 2005; 11: 63-70.
106. Bouloumie A, Drexler HCA, Lafontan M, Busse R. Leptin, the Product of Ob Gene, Promotes Angiogenesis, Circ Res 1998; 83: 1059-1066.
107. Grasso, P., Lee, D.W., Leinung, M.C.: US20077186694B2 (2007).
108. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci USA 2001; 98: 6390-6395.
109. Reaume, A., Saporito, M.S.: WO07024863 (2007).
110. Peelman F, Couturier C, Dam J, Zabeau L, Tavernier J, Jockers R. Techniques: New pharmacological perspectives for the leptin receptor. Trends Pharmacol Sci 2006; 27: 218-225.
111. Rozhavskaya-Arena M, Lee DW, Leinung MC, Grasso P. Design of a synthetic leptin agonist: effects on energy balance, glucose homeostasis, and thermoregulation. Endocrinology 2000; 141: 2501-2507.
112. Salonen, J.T., Todorova, B., Aalto, J-M., Kontkanen, O., Pirakanen, M., Uimari, P.: WO07006858 (2007).